Myocardial Revascularization in Patients with Left Ventricular Dysfunction
Do patients with ischemic cardiomyopathy benefit from surgical revascularization? This question has been studied extensively over the last 20–30 years and needs to be analyzed from different viewpoints. What is the evidence concerning surgical revascularization of patients with an ejection fraction of 35%? What is the role of percutaneous coronary interventions (PCI) and optimal medical therapy (OMT). What do the guidelines tell us? And are current strategies still timely in view of new developments in the field of end-stage heart failure?
- 14.Marui A, Kimura T, Nishiwaki N, et al. Comparison of five-year outcomes of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions≤50% versus >50% (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol. 2014;114:988–96.CrossRefGoogle Scholar
- 19.Yang JH, Choi SH, Song YB, Hahn JY, Choi JH, Jeong DS, Sung K, Kim WS, Lee YT, Gwon HC. Long-term outcomes of drug-eluting stent implantation versus coronary artery bypass grafting for patients with coronary artery disease and chronic left ventricular systolic dysfunction. Am J Cardiol. 2013;112:623–9.CrossRefGoogle Scholar
- 21.Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2014;35:2541–619.CrossRefGoogle Scholar
- 23.Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.CrossRefGoogle Scholar